Elevated levels and altered fatty acid composition of plasma lysophosphatidylcholine(lysoPC) in ovarian cancer patients

Misako Okita, Douglas C. Gaudette, Gordon Mills, Bruce J. Holub

Research output: Contribution to journalArticle

122 Citations (Scopus)

Abstract

Lysophosphatidylcholine (lysoPC), a product of phosphatidylcholine (PC) hydrolysis via phospholipase A activity, has been proposed to activate cells from a number of lineages, Here, we demonstrate that lysoPC levels are significantly elevated (by 43% overall, relative to normal controls) in the plasma of ovarian cancer patients. This does not appear to be common to all cancers as 5 out of 6 leukemia patients tested had markedly lower (less than one-half of normal) plasma lysoPC. In the plasma of ovarian cancer patients, the percentages of palmitoyl- and stearoyl-lysoPC species were significantly higher, whereas oleoyl and particularly linoleoyl/lysoPC were significantly lower than in control subjects. The molar ratios of lysoPC/PC and palmitoyl-lysoPC/linoleoy/lysoPC were also significantly elevated in the plasma of ovarian cancer patients compared with those of control subjects. Furthermore, the calculated value of plasma (lysoPC/PC) x (palmitoyl-lysoPC/linoleoyl lysoPC) was markedly higher in patients compared with controls.

Original languageEnglish (US)
Pages (from-to)31-34
Number of pages4
JournalInternational Journal of Cancer
Volume71
Issue number1
DOIs
StatePublished - Apr 23 1997
Externally publishedYes

Fingerprint

Lysophosphatidylcholines
Ovarian Neoplasms
Fatty Acids
Phosphatidylcholines
Phospholipases A
Leukemia
Hydrolysis
Cell Count

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Elevated levels and altered fatty acid composition of plasma lysophosphatidylcholine(lysoPC) in ovarian cancer patients. / Okita, Misako; Gaudette, Douglas C.; Mills, Gordon; Holub, Bruce J.

In: International Journal of Cancer, Vol. 71, No. 1, 23.04.1997, p. 31-34.

Research output: Contribution to journalArticle

@article{64cd707b595840f7b0b3a407ba43996c,
title = "Elevated levels and altered fatty acid composition of plasma lysophosphatidylcholine(lysoPC) in ovarian cancer patients",
abstract = "Lysophosphatidylcholine (lysoPC), a product of phosphatidylcholine (PC) hydrolysis via phospholipase A activity, has been proposed to activate cells from a number of lineages, Here, we demonstrate that lysoPC levels are significantly elevated (by 43{\%} overall, relative to normal controls) in the plasma of ovarian cancer patients. This does not appear to be common to all cancers as 5 out of 6 leukemia patients tested had markedly lower (less than one-half of normal) plasma lysoPC. In the plasma of ovarian cancer patients, the percentages of palmitoyl- and stearoyl-lysoPC species were significantly higher, whereas oleoyl and particularly linoleoyl/lysoPC were significantly lower than in control subjects. The molar ratios of lysoPC/PC and palmitoyl-lysoPC/linoleoy/lysoPC were also significantly elevated in the plasma of ovarian cancer patients compared with those of control subjects. Furthermore, the calculated value of plasma (lysoPC/PC) x (palmitoyl-lysoPC/linoleoyl lysoPC) was markedly higher in patients compared with controls.",
author = "Misako Okita and Gaudette, {Douglas C.} and Gordon Mills and Holub, {Bruce J.}",
year = "1997",
month = "4",
day = "23",
doi = "10.1002/(SICI)1097-0215(19970328)71:1<31::AID-IJC7>3.0.CO;2-4",
language = "English (US)",
volume = "71",
pages = "31--34",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "1",

}

TY - JOUR

T1 - Elevated levels and altered fatty acid composition of plasma lysophosphatidylcholine(lysoPC) in ovarian cancer patients

AU - Okita, Misako

AU - Gaudette, Douglas C.

AU - Mills, Gordon

AU - Holub, Bruce J.

PY - 1997/4/23

Y1 - 1997/4/23

N2 - Lysophosphatidylcholine (lysoPC), a product of phosphatidylcholine (PC) hydrolysis via phospholipase A activity, has been proposed to activate cells from a number of lineages, Here, we demonstrate that lysoPC levels are significantly elevated (by 43% overall, relative to normal controls) in the plasma of ovarian cancer patients. This does not appear to be common to all cancers as 5 out of 6 leukemia patients tested had markedly lower (less than one-half of normal) plasma lysoPC. In the plasma of ovarian cancer patients, the percentages of palmitoyl- and stearoyl-lysoPC species were significantly higher, whereas oleoyl and particularly linoleoyl/lysoPC were significantly lower than in control subjects. The molar ratios of lysoPC/PC and palmitoyl-lysoPC/linoleoy/lysoPC were also significantly elevated in the plasma of ovarian cancer patients compared with those of control subjects. Furthermore, the calculated value of plasma (lysoPC/PC) x (palmitoyl-lysoPC/linoleoyl lysoPC) was markedly higher in patients compared with controls.

AB - Lysophosphatidylcholine (lysoPC), a product of phosphatidylcholine (PC) hydrolysis via phospholipase A activity, has been proposed to activate cells from a number of lineages, Here, we demonstrate that lysoPC levels are significantly elevated (by 43% overall, relative to normal controls) in the plasma of ovarian cancer patients. This does not appear to be common to all cancers as 5 out of 6 leukemia patients tested had markedly lower (less than one-half of normal) plasma lysoPC. In the plasma of ovarian cancer patients, the percentages of palmitoyl- and stearoyl-lysoPC species were significantly higher, whereas oleoyl and particularly linoleoyl/lysoPC were significantly lower than in control subjects. The molar ratios of lysoPC/PC and palmitoyl-lysoPC/linoleoy/lysoPC were also significantly elevated in the plasma of ovarian cancer patients compared with those of control subjects. Furthermore, the calculated value of plasma (lysoPC/PC) x (palmitoyl-lysoPC/linoleoyl lysoPC) was markedly higher in patients compared with controls.

UR - http://www.scopus.com/inward/record.url?scp=0030976523&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030976523&partnerID=8YFLogxK

U2 - 10.1002/(SICI)1097-0215(19970328)71:1<31::AID-IJC7>3.0.CO;2-4

DO - 10.1002/(SICI)1097-0215(19970328)71:1<31::AID-IJC7>3.0.CO;2-4

M3 - Article

C2 - 9096662

AN - SCOPUS:0030976523

VL - 71

SP - 31

EP - 34

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 1

ER -